Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine Hydrochloride / Tropicamide, the active ingredients in Mydriasert, are mydriatic agents presented as a topical ophthalmic solution for ocular use. They facilitate rapid pupil dilation for diagnostic eye examinations and ocular surgery. GNH USA supplies Mydriasert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Mydriasert, a combination mydriatic eye drop, is employed to induce pupil dilation in ophthalmic examinations and procedures.

- Diagnostic eye examinations: provides rapid and sufficient mydriasis for fundus evaluation. - Ocular surgery: facilitates adequate pupil dilation during cataract or intra‑ocular procedures. - Laser retinal therapy: enables proper exposure of retinal tissue for laser treatment.

Mydriasert may cause ocular and systemic reactions following topical administration.

Common Side Effects: - Transient blurred vision: temporary loss of visual clarity after instillation. - Photophobia: increased sensitivity to light due to pupil dilation. - Ocular irritation: mild burning or stinging sensation. - Conjunctival redness: mild hyperemia of the eye. - Elevated intra‑ocular pressure: short‑term rise in pressure, especially in glaucoma‑susceptible patients. - Allergic conjunctivitis: mild allergic response of the conjunctiva.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma: sudden, severe increase in intra‑ocular pressure. - Persistent mydriasis: prolonged pupil dilation beyond the expected duration. - Severe allergic reaction: anaphylaxis or angioedema. - Systemic hypertension: notable rise in blood pressure after absorption. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Severe ocular inflammation: uveitis or keratitis.

Prior to using Mydriasert, consider the following safety measures.

- Assess intra‑ocular pressure: measure IOP in patients with glaucoma risk. - Evaluate allergy history: avoid if hypersensitivity to phenylephrine, tropicamide, or excipients exists. - Use caution in cardiovascular disease: monitor blood pressure in patients with hypertension or coronary conditions. - Avoid in pediatric patients: limited safety data; use only under specialist supervision. - Consider systemic drug interactions: review concomitant adrenergic or anticholinergic agents. - Store at room temperature: keep in the original container, protect from light and moisture.

Mydriasert can interact with other medications; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Systemic sympathomimetics (e.g., epinephrine): additive cardiovascular effects. - Anticholinergic drugs (e.g., atropine): excessive mydriasis and systemic anticholinergic load. - Beta‑blockers: may mask tachycardia induced by phenylephrine. - Tricyclic antidepressants: increased risk of hypertension.

Moderate Interactions (Monitor Closely): - Topical ocular anesthetics: may enhance corneal toxicity. - Other mydriatics: cumulative pupil dilation. - Systemic antihypertensives: may blunt phenylephrine effect. - Antihistamines: increased anticholinergic side effects. - Diabetes medications: monitor blood glucose if systemic absorption occurs.